Across TCGA pan-cancer cohorts, GRM7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GRM7 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GRM7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GRM7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD and GBM are the cancer types where GRM7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.851	0.564	.014	5	view →
GBM	DFS	Tertile	All	0.834	0.671	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: GRM7 tumor-vs-normal RNA expression · all GRM7 data types